Rapid cTnI/Hs-cTnI Testing: Transforming Cardiac Diagnosis

cTnI and Hs-Ctni: Clinical Significance and Diagnostic Challenges

Cardiac Troponin I (cTnI) and High-Sensitivity Troponin I (Hs-cTnI) serve as critical biomarkers for diagnosing acute myocardial inFarction (AMI) and evaluating myocardial injury. Early, precise detection is vital for accelerating diagnosis in patients with chest pain, guiding clinical interventions (e.g., reperfusion therapy), and improving outcomes. Traditional cTnI assays face limitations in sensitivity and early diagnostic windows, highlighting the need for next-generation solutions that deliver ultra-high sensitivity, speed, and reliability.

Ultra-Sensitive Diagnosis and Rapid Testing

Our next-generation Hs-cTnI/cTnI Dual-Mode Detection Platform employs advanced Fluorescence Immunoassay (FIA) technology, delivering results within 15 minutes with a sensitivity of 0.5 ng/L (Hs-cTnI) and specificity >99.5%. This system enables:

 

Precise differentiation between acute/chronic myocardial injury through dynamic cTnI monitoring;

 

Classification of Type 1/Type 2 MI to guide personalized treatment;

 

Seamless integration with chest pain center triage protocols, reducing non-cardiac case processing time.

 

Core Applications:

 

Emergency Chest Pain Evaluation: Rapidly rule in/out AMI to shorten Door-to-Balloon (D2B) time;

 

High-Risk Population Screening: Early detection of asymptomatic myocardial injury in diabetic or CKD patients;

 

Postoperative Cardiac Monitoring: Real-time cardiotoxicity assessment for post-surgical or chemotherapy patients.

Multi-Scenario Deployment and End-to-End Management

1. Critical Care Management

 

Risk Stratification: Hs-cTnI >14 ng/L (baseline) indicates high-risk MI requiring urgent intervention;

 

Treatment Efficacy Tracking: Dynamic cTnI monitoring post-reperfusion evaluates therapeutic outcomes.

 

2. Chronic Disease Surveillance

 

Occult Myocardial Injury Screening: Regular Hs-cTnI testing for HF/hypertension patients predicts adverse events;

 

Drug Safety Management: Detects subclinical injury during chemo/immunotherapy.

 

3. Public Health Coordination

 

Chest Pain Center QA: Standardized data supports healthcare quality metrics;

 

Regional MI Response Networks: Real-time data sharing optimizes emergency resource allocation.

 

Aehealth’s  Lamuno Platform: Powering Precision Cardiovascular Diagnostics

POCT Point-of-Care Solution:

 

Rapid Results: 15-minute Hs-cTnI quantification aligns with ESC "1-hour triage" guidelines;

 

Direct Whole-Blood Testing: Processes serum/plasma/whole blood without centrifugation;

 

Smart Connectivity: Auto-syncs data to hospital LIS/HIS systems.

 

High-Throughput Automated Solution:

 

Processes >500 tests/day via multi-channel parallel detection;

 

Compact design adaptable to labs, ERs, and mobile units;

 

User-friendly operation requiring no specialized training.

 

From Early Warning to Intervention: Aehealth’s Comprehensive Cardiovascular Health Management

The Aehealth Lamuno platform transforms cardiac care by integrating ultra-early myocardial injury detection with dynamic risk assessment:

 

Emergency Settings: Reduces unnecessary angiograms and healthcare costs;

 

Chronic Disease Management: Predicts MI risk 6-12 hours earlier, improving survival rates;

 

Public Health: Advances regional chest pain center networks in alignment with WHO cardiovascular initiatives.

 

Data-Driven Decisions, Technology-Guided Care – Aehealth leads the new era of precision cardiovascular diagnostics.

AEHEALTH LIMITED, is the fast growing POCT company. Manufacture and sales of rapid diagnostic reagents and related equipment in IVD field.

The product application is covering areas like small clinics, ambulances, customs, ICU, homes, natural disaster rescue, third- party laboratories, etc. To achieve the stability of quanlity control, Aehealth obtained multiple certifications like ISO13485 and CE MARK for the quality control management system.